ANN ARBOR, Mich., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 2026 Citizens Life Sciences Conference on March 11, 2026, at 8:25 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. About Esperion Thera ...

Company Overview - Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on developing innovative therapies for cardiometabolic and rare/orphan diseases [3] - The company markets two oral, once-daily, non-statin therapies aimed at patients struggling to maintain low-density lipoprotein cholesterol (LDL-C) levels and at risk of cardiovascular disease [3] Upcoming Event - Esperion will present at J.P. Morgan's 44th Annual Healthcare Conference on January 14, 2025, starting at 2:15 p.m. PT/5:15 p.m. ET [1] - A live webcast of the presentation will be available on the investor and media section of the Esperion website, with a replay accessible approximately two hours after the event [2] Market Position and Strategy - Esperion has a broad U.S. commercial infrastructure and has received global approvals in over 40 countries, positioning itself as a partner-of-choice for global innovators seeking U.S. market access [4] - The company is advancing its leadership in ACLY biology to build a diversified pipeline of novel product candidates, including treatments for Primary Sclerosing Cholangitis and renal diseases [4]